McGill University Health Centre/Research Institute of the McGill University Health Centre
muhc.caTotal trials
405
Active
97
Phase 3
39
Total enrollment
104,498
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 48 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| acetaminophen | — | — | — | — | 2 | ||
| Dabigatran | — | — | — | — | — | 1 | |
| Apixaban | — | — | — | — | — | 1 | |
| edoxaban | — | — | — | — | — | 1 | |
| Rivaroxaban | — | — | — | — | — | 1 | |
| Systemic corticosteroids | — | — | — | — | — | 1 | |
| Invokana 300 mg and 100 mg | — | — | — | — | — | 1 | |
| B/F/TAF | — | — | — | — | — | 1 | |
| Ustekinumab 90 mg SC q8w | — | — | — | — | — | 1 | |
| Ustekinumab 90 mg SC q12w | — | — | — | — | — | 1 | |
| Empagliflozin | — | — | — | — | — | 1 | |
| Clindamycin + primaquine | — | — | — | — | — | 1 | |
| Pentamidine | — | — | — | — | — | 1 | |
| Atovaquone | — | — | — | — | — | 1 | |
| Normal saline | — | — | — | 4 | |||
| Dexamethasone | — | — | — | — | 2 | ||
| Vancomycin | — | — | — | — | — | 2 | |
| rifampin double dose | — | — | — | — | 2 | ||
| Fidaxomicin | — | — | — | — | — | 1 | |
| Oral Vancomycin Prophylaxis | — | — | — | — | — | 1 | |
| rifampin standard arm | — | — | — | — | — | 1 | |
| levofloxacin and rifapentine | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Intervention Period 1: Semaglutide + Empagliflozin | — | — | — | — | — | 1 | |
| Intervention Period 2: Semaglutide + Empagliflozin Placebo | — | — | — | — | — | 1 | |
| Intervention Period 3: Semaglutide Placebo + Empagliflozin | — | — | — | — | — | 1 | |
| Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo | — | — | — | — | — | 1 | |
| Semaglutide with 4 meal strategies | — | — | — | — | — | 1 | |
| Canagliflozin 300Mg Tab | — | — | — | — | — | 1 | |
| dexmedetomidine (perineural) 0.67 mcg/kg | — | — | — | — | — | 1 | |
| dexmedetomidine (perineural) 1 mcg/kg | — | — | — | — | — | 1 | |
| dexmedetomidine (perineural) 1.33 mcg/kg | — | — | — | — | — | 1 | |
| Canagliflozin 300 MG | — | — | — | — | — | 1 | |
| Inactivated influenza vaccine (IIV) at baseline | — | — | — | — | — | 1 | |
| COVID-19 Vaccines at a 3-month interval | — | — | — | — | — | 1 | |
| Inactivated influenza vaccine at Month 1 | — | — | — | — | — | 1 | |
| COVID-19 Vaccines at a 6-month interval | — | — | — | — | — | 1 | |
| Eligard | — | — | — | — | — | 1 | |
| Metformin | — | — | — | 3 | |||
| Sildenafil Citrate | — | — | — | — | — | 1 |
8 more active programs hidden
Next readouts
- 2021-10-20
- 2021-12-31
- 2025-05
- 2026-03-30
- 2026-06-01
- 2026-06-30
- 2026-07
- 2026-10-31
- 2026-12-15
- 2027-01
Top conditions
- COPD7
- HIV Infections7
- Type 1 Diabetes7
- Parkinson's Disease6
- Diabetes Mellitus, Type 16
- HIV6
- Coronary Artery Disease5
- Postoperative Pain5
Frequently asked questions about McGill University Health Centre/Research Institute of the McGill University Health Centre
- How many clinical trials does McGill University Health Centre/Research Institute of the McGill University Health Centre have on ClinicalTrials.gov?
- McGill University Health Centre/Research Institute of the McGill University Health Centre is listed as the lead sponsor on 405 clinical trials in ClinicalTrials.gov, 97 of which are currently active (recruiting, enrolling, or ongoing).
- How many of McGill University Health Centre/Research Institute of the McGill University Health Centre's trials are in Phase 3?
- 39 of McGill University Health Centre/Research Institute of the McGill University Health Centre's trials are in Phase 3, spread across 48 active drug programs.
- What therapeutic areas does McGill University Health Centre/Research Institute of the McGill University Health Centre focus on?
- McGill University Health Centre/Research Institute of the McGill University Health Centre's most-studied conditions on ClinicalTrials.gov are COPD, HIV Infections, Type 1 Diabetes, Parkinson's Disease, Diabetes Mellitus, Type 1.
- When are McGill University Health Centre/Research Institute of the McGill University Health Centre's next clinical trial readouts?
- McGill University Health Centre/Research Institute of the McGill University Health Centre has 10 upcoming primary-completion readouts tracked here; the soonest is “Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM”, expected around 2021-10-20.